Oxford BioTherapeutics
Details
About Oxford BioTherapeutics
Oxford BioTherapeutics (OBT) is a clinical-stage biotechnology company focused on developing innovative antibody-based therapeutics for the treatment of cancer. The company leverages its proprietary OGAP® platform, which is the world’s largest cancer-specific membrane protein library, to discover novel, highly tumour-specific antigens for first-in-class antibody-drug conjugates (ADCs), Bispecific T-cell Engagers (BITE®), and CAR-based therapeutics. OBT's lead asset, OBT076, is currently in Phase 1b clinical development, supported by collaborations with industry leaders such as Roche, GSK, Bristol Myers Squibb, Boehringer Ingelheim, and Zymeworks.
Career Opportunities
Oxford BioTherapeutics offers a dynamic working environment that fosters professional growth and collaboration among its team members. The company is committed to driving innovation in drug discovery and provides employees with opportunities to contribute to impactful projects in the field of immuno-oncology.
- Collaborative work culture
- Opportunities for professional development
- Engagement in cutting-edge research
